CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues
Product sales	$ 2,200	$ 2,389	$ 4,276	$ 4,725
Other revenues	33	31	66	67
Total revenues	2,233	2,420	4,342	4,792
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	635	648	1,219	1,268
Cost of other revenues	11	10	23	20
Selling, general and administrative	659	671	1,320	1,484
Research and development	94	124	190	227
Amortization of intangible assets	623	673	1,258	1,351
Asset impairments	85	230	223	246
Restructuring and integration costs	18	20	36	58
Acquired in-process research and development costs	1	2	5	3
Acquisition-related contingent consideration	(49)	7	(59)	9
Other income, net	(19)	(46)	(259)	(21)
Total expenses	2,058	2,339	3,956	4,645
Operating income	175	81	386	147
Interest income	3	2	6	3
Interest expense	(459)	(472)	(933)	(899)
Loss on extinguishment of debt	0	0	(64)	0
Foreign exchange and other	39	12	68	6
Loss before recovery of income taxes	(242)	(377)	(537)	(743)
Recovery of income taxes	(205)	(73)	(1,129)	(66)
Net (loss) income	(37)	(304)	592	(677)
Less: Net income (loss) attributable to noncontrolling interest	1	(2)	2	(1)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (38)	$ (302)	$ 590	$ (676)
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$ (0.11)	$ (0.88)	$ 1.69	$ (1.96)
Diluted (in usd per share)	$ (0.11)	$ (0.88)	$ 1.68	$ (1.96)
Weighted-average common shares
Basic (in shares)	350.1	345.0	350.0	344.9
Diluted (in shares)	350.1	345.0	350.9	344.9